BIOGEN INC (IDP.DE) Stock Fundamental Analysis
Europe - FRA:IDP - US09062X1037 - Common Stock
129.65 EUR
+2.35 (+1.85%)
Taking everything into account, IDP scores 5 out of 10 in our fundamental rating. IDP was compared to 73 industry peers in the Biotechnology industry. IDP has an excellent financial health rating, but there are some minor concerns on its profitability. IDP is cheap, but on the other hand it scores bad on growth. These ratings could make IDP a good candidate for value investing.
1. Profitability
1.1 Basic Checks
In the past year IDP was profitable.
IDP had a positive operating cash flow in the past year.
IDP had positive earnings in each of the past 5 years.
In the past 5 years IDP always reported a positive cash flow from operatings.
1.2 Ratios
With a decent Return On Assets value of 5.40%, IDP is doing good in the industry, outperforming 79.22% of the companies in the same industry.
The Return On Equity of IDP (8.68%) is better than 80.52% of its industry peers.
With an excellent Return On Invested Capital value of 9.52%, IDP belongs to the best of the industry, outperforming 84.42% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for IDP is below the industry average of 14.02%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.4% | ||
| ROE | 8.68% | ||
| ROIC | 9.52% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
1.3 Margins
With an excellent Profit Margin value of 15.31%, IDP belongs to the best of the industry, outperforming 83.12% of the companies in the same industry.
IDP's Profit Margin has declined in the last couple of years.
IDP has a better Operating Margin (27.35%) than 85.71% of its industry peers.
IDP's Operating Margin has declined in the last couple of years.
IDP's Gross Margin of 75.43% is fine compared to the rest of the industry. IDP outperforms 68.83% of its industry peers.
In the last couple of years the Gross Margin of IDP has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.35% | ||
| PM (TTM) | 15.31% | ||
| GM | 75.43% |
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
2. Health
2.1 Basic Checks
IDP has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, IDP has more shares outstanding
The number of shares outstanding for IDP has been reduced compared to 5 years ago.
IDP has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 3.11 indicates that IDP is not in any danger for bankruptcy at the moment.
IDP has a Altman-Z score of 3.11. This is in the better half of the industry: IDP outperforms 68.83% of its industry peers.
IDP has a debt to FCF ratio of 3.40. This is a good value and a sign of high solvency as IDP would need 3.40 years to pay back of all of its debts.
IDP's Debt to FCF ratio of 3.40 is amongst the best of the industry. IDP outperforms 80.52% of its industry peers.
A Debt/Equity ratio of 0.36 indicates that IDP is not too dependend on debt financing.
IDP has a Debt to Equity ratio (0.36) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.36 | ||
| Debt/FCF | 3.4 | ||
| Altman-Z | 3.11 |
ROIC/WACC1.06
WACC8.99%
2.3 Liquidity
IDP has a Current Ratio of 2.50. This indicates that IDP is financially healthy and has no problem in meeting its short term obligations.
IDP has a Current ratio of 2.50. This is comparable to the rest of the industry: IDP outperforms 55.84% of its industry peers.
IDP has a Quick Ratio of 1.79. This is a normal value and indicates that IDP is financially healthy and should not expect problems in meeting its short term obligations.
IDP has a Quick ratio (1.79) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.5 | ||
| Quick Ratio | 1.79 |
3. Growth
3.1 Past
IDP shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -3.61%.
Measured over the past years, IDP shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -13.31% on average per year.
Looking at the last year, IDP shows a small growth in Revenue. The Revenue has grown by 3.36% in the last year.
IDP shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -7.62% yearly.
EPS 1Y (TTM)-3.61%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%3.6%
Revenue 1Y (TTM)3.36%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%7.33%
3.2 Future
IDP is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 1.15% yearly.
The Revenue is expected to decrease by -0.44% on average over the next years.
EPS Next Y-2.25%
EPS Next 2Y-0.87%
EPS Next 3Y0.6%
EPS Next 5Y1.15%
Revenue Next Year0.43%
Revenue Next 2Y-1.77%
Revenue Next 3Y-1.1%
Revenue Next 5Y-0.44%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 9.40 indicates a reasonable valuation of IDP.
IDP's Price/Earnings ratio is rather cheap when compared to the industry. IDP is cheaper than 92.21% of the companies in the same industry.
IDP is valuated cheaply when we compare the Price/Earnings ratio to 26.89, which is the current average of the S&P500 Index.
IDP is valuated reasonably with a Price/Forward Earnings ratio of 9.30.
96.10% of the companies in the same industry are more expensive than IDP, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 22.99. IDP is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.4 | ||
| Fwd PE | 9.3 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of IDP indicates a rather cheap valuation: IDP is cheaper than 90.91% of the companies listed in the same industry.
IDP's Price/Free Cash Flow ratio is rather cheap when compared to the industry. IDP is cheaper than 92.21% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.95 | ||
| EV/EBITDA | 7.36 |
4.3 Compensation for Growth
IDP has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.87%
EPS Next 3Y0.6%
5. Dividend
5.1 Amount
No dividends for IDP!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:IDP (10/24/2025, 7:00:00 PM)
129.65
+2.35 (+1.85%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners92.49%
Inst Owner ChangeN/A
Ins Owners0.14%
Ins Owner ChangeN/A
Market Cap19.01B
Revenue(TTM)10.00B
Net Income(TTM)1.53B
Analysts73.81
Price Target148.15 (14.27%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)28.1%
Min EPS beat(2)17.28%
Max EPS beat(2)38.92%
EPS beat(4)4
Avg EPS beat(4)15.59%
Min EPS beat(4)0.67%
Max EPS beat(4)38.92%
EPS beat(8)8
Avg EPS beat(8)13.06%
EPS beat(12)12
Avg EPS beat(12)11.49%
EPS beat(16)14
Avg EPS beat(16)10.96%
Revenue beat(2)2
Avg Revenue beat(2)9.15%
Min Revenue beat(2)6.67%
Max Revenue beat(2)11.62%
Revenue beat(4)3
Avg Revenue beat(4)4.43%
Min Revenue beat(4)-0.68%
Max Revenue beat(4)11.62%
Revenue beat(8)5
Avg Revenue beat(8)1.84%
Revenue beat(12)8
Avg Revenue beat(12)1.78%
Revenue beat(16)11
Avg Revenue beat(16)1.73%
PT rev (1m)1.07%
PT rev (3m)-3.09%
EPS NQ rev (1m)0.91%
EPS NQ rev (3m)-1.96%
EPS NY rev (1m)-0.55%
EPS NY rev (3m)5.44%
Revenue NQ rev (1m)-0.08%
Revenue NQ rev (3m)2.63%
Revenue NY rev (1m)0.03%
Revenue NY rev (3m)4.45%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.4 | ||
| Fwd PE | 9.3 | ||
| P/S | 2.21 | ||
| P/FCF | 11.95 | ||
| P/OCF | 10.43 | ||
| P/B | 1.25 | ||
| P/tB | 13.19 | ||
| EV/EBITDA | 7.36 |
EPS(TTM)13.79
EY10.64%
EPS(NY)13.94
Fwd EY10.75%
FCF(TTM)10.85
FCFY8.37%
OCF(TTM)12.43
OCFY9.59%
SpS58.72
BVpS103.58
TBVpS9.83
PEG (NY)N/A
PEG (5Y)N/A
Graham Number179.27
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.4% | ||
| ROE | 8.68% | ||
| ROCE | 10.87% | ||
| ROIC | 9.52% | ||
| ROICexc | 10.7% | ||
| ROICexgc | 37.26% | ||
| OM | 27.35% | ||
| PM (TTM) | 15.31% | ||
| GM | 75.43% | ||
| FCFM | 18.47% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
ROICexc(3y)12.43%
ROICexc(5y)16.11%
ROICexgc(3y)38.35%
ROICexgc(5y)40.12%
ROCE(3y)12.07%
ROCE(5y)15.58%
ROICexgc growth 3Y14.15%
ROICexgc growth 5Y-5.35%
ROICexc growth 3Y-15.93%
ROICexc growth 5Y-20.8%
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
F-Score6
Asset Turnover0.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.36 | ||
| Debt/FCF | 3.4 | ||
| Debt/EBITDA | 1.81 | ||
| Cap/Depr | 36.28% | ||
| Cap/Sales | 2.7% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 60.86% | ||
| Profit Quality | 120.66% | ||
| Current Ratio | 2.5 | ||
| Quick Ratio | 1.79 | ||
| Altman-Z | 3.11 |
F-Score6
WACC8.99%
ROIC/WACC1.06
Cap/Depr(3y)54.43%
Cap/Depr(5y)68.89%
Cap/Sales(3y)3.09%
Cap/Sales(5y)3.21%
Profit Quality(3y)99.34%
Profit Quality(5y)120.98%
High Growth Momentum
Growth
EPS 1Y (TTM)-3.61%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%3.6%
EPS Next Y-2.25%
EPS Next 2Y-0.87%
EPS Next 3Y0.6%
EPS Next 5Y1.15%
Revenue 1Y (TTM)3.36%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%7.33%
Revenue Next Year0.43%
Revenue Next 2Y-1.77%
Revenue Next 3Y-1.1%
Revenue Next 5Y-0.44%
EBIT growth 1Y23.31%
EBIT growth 3Y-8.8%
EBIT growth 5Y-18.9%
EBIT Next Year7.73%
EBIT Next 3Y2.84%
EBIT Next 5Y5.8%
FCF growth 1Y64.41%
FCF growth 3Y-9.06%
FCF growth 5Y-17.06%
OCF growth 1Y48.2%
OCF growth 3Y-7.56%
OCF growth 5Y-16.49%
BIOGEN INC / IDP.DE FAQ
What is the ChartMill fundamental rating of BIOGEN INC (IDP.DE) stock?
ChartMill assigns a fundamental rating of 5 / 10 to IDP.DE.
Can you provide the valuation status for BIOGEN INC?
ChartMill assigns a valuation rating of 7 / 10 to BIOGEN INC (IDP.DE). This can be considered as Undervalued.
What is the profitability of IDP stock?
BIOGEN INC (IDP.DE) has a profitability rating of 6 / 10.
Can you provide the financial health for IDP stock?
The financial health rating of BIOGEN INC (IDP.DE) is 6 / 10.
Can you provide the expected EPS growth for IDP stock?
The Earnings per Share (EPS) of BIOGEN INC (IDP.DE) is expected to decline by -2.25% in the next year.